<DOC>
	<DOCNO>NCT03055962</DOCNO>
	<brief_summary>Study E2609-J081-014 single-center , randomize , double-blind , placebo-controlled study conduct evaluate safety tolerability multiple oral dos E2609 50 milligram ( mg ) , administer daily 14 day , healthy Japanese participant age 50 85 year .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability Once Daily Dose 50 mg E2609 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female Aged 50 85 year , inclusive time consent Body mass index ( BMI ) 17.6 32 kilogram per meter square ( kg/m^2 ) Screening Personal family history seizure disorder , symptomatic seizure ( include history simple febrile seizure childhood ) past present medical condition , opinion investigator potential reduce seizure threshold ( eg , history head trauma concussion , previous alcohol abuse , substance abuse ) A history cerebrovascular accident nonvasovagalrelated loss consciousness Any clinically significant finding neurological examination A family history Long QT Syndrome presence risk factor Torsades de Pointes ( TDP ) , hypokalemia , hypomagnesemia , hypocalcemia History cardiac arrhythmia , ischemic heart disease , cerebrovascular disease A history gastrointestinal surgery may affect pharmacokinetic profile E2609 ( eg , hepatectomy , nephrotomy , digestive organ resection ) A known history clinically significant drug food allergy presently experience significant seasonal allergy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy Participants</keyword>
	<keyword>E2609</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japan</keyword>
</DOC>